Patents by Inventor Noorjahan A. Panjwani

Noorjahan A. Panjwani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tissue-engineered silk organs
    Patent number: 10478524
    Abstract: This invention relates to a lamellae tissue layer, comprising a grooved silk fibroin substrate comprising tissue-specific cells. The silk fibroin substrates provides an excellent means of controlling and culturing cell and extracellular matrix development. A multitude of lamellae tissue layers can be used to create a tissue-engineered organ, such as a tissue-engineered cornea. The tissue-engineered organ is non-immunogenic and biocompatible.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: November 19, 2019
    Assignee: TRUSTEES OF TUFTS COLLEGE
    Inventors: David L. Kaplan, Fiorenzo G. Omenetto, Jeffrey K. Marchant, Noorjahan Panjwani, Brian Lawrence
  • Lymphangiogenesis inhibitors for cancer and for graft survival
    Patent number: 10226509
    Abstract: Compositions and methods are provided for treating and/or preventing lymphangiogenesis in a subject by using an inhibitor of a galectin-8 protein in an amount effective to inhibit or to modulate an activity of the galectin-8 protein or a portion thereof sufficient to inhibit the lymphangiogenesis associated with cancer, corneal injury, dry eye disease, inflammation, lymphedema, organ rejection or graft rejection.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: March 12, 2019
    Assignee: Tufts University
    Inventors: Noorjahan Panjwani, Wei-Sheng Chen
  • TISSUE-ENGINEERED SILK ORGANS
    Publication number: 20180036453
    Abstract: This invention relates to a lamellae tissue layer, comprising a grooved silk fibroin substrate comprising tissue-specific cells. The silk fibroin substrates provides an excellent means of controlling and culturing cell and extracellular matrix development. A multitude of lamellae tissue layers can be used to create a tissue-engineered organ, such as a tissue-engineered cornea. The tissue-engineered organ is non-immunogenic and biocompatible.
    Type: Application
    Filed: May 19, 2017
    Publication date: February 8, 2018
    Inventors: David L. Kaplan, Fiorenzo G. Omenetto, Jeffrey K. Marchant, Noorjahan Panjwani, Brian Lawrence
  • Lymphangiogenesis inhibitors for cancer and for graft survival
    Publication number: 20170202915
    Abstract: Compositions and methods are provided for treating and/or preventing lymphangiogenesis in a subject by using an inhibitor of a galectin-8 protein in an amount effective to inhibit or to modulate an activity of the galectin-8 protein or a portion thereof sufficient to inhibit the lymphangiogenesis associated with cancer, corneal injury, dry eye disease, inflammation, lymphedema, organ rejection or graft rejection.
    Type: Application
    Filed: December 23, 2016
    Publication date: July 20, 2017
    Applicant: TUFTS UNIVERSITY
    Inventors: Noorjahan Panjwani, Wei-Sheng Chen
  • Tissue-engineered silk organs
    Patent number: 9655993
    Abstract: This invention relates to a lamellae tissue layer, comprising a grooved silk fibroin substrate comprising tissue-specific cells. The silk fibroin substrates provides an excellent means of controlling and culturing cell and extracellular matrix development. A multitude of lamellae tissue layers can be used to create a tissue-engineered organ, such as a tissue-engineered cornea. The tissue-engineered organ is non-immunogenic and biocompatible.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: May 23, 2017
    Assignee: Trustees of Tufts College
    Inventors: David L. Kaplan, Fiorenzo Omenetto, Jeffrey K. Marchant, Noorjahan Panjwani, Brian Lawrence
  • TISSUE-ENGINEERED SILK ORGANS
    Publication number: 20160151538
    Abstract: This invention relates to a lamellae tissue layer, comprising a grooved silk fibroin substrate comprising tissue-specific cells. The silk fibroin substrates provides an excellent means of controlling and culturing cell and extracellular matrix development. A multitude of lamellae tissue layers can be used to create a tissue-engineered organ, such as a tissue-engineered cornea. The tissue-engineered organ is non-immunogenic and biocompatible.
    Type: Application
    Filed: July 7, 2015
    Publication date: June 2, 2016
    Inventors: David L. Kaplan, Fiorenzo Omenetto, Jeffrey K. Marchant, Noorjahan Panjwani, Brian Lawrence
  • Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
    Publication number: 20150320782
    Abstract: Methods and kits using a pharmaceutical composition for use in inhibiting ocular angiogenesis or fibrosis are provided herein, such that composition includes a pharmaceutically suitable carrier or diluent and an amount of the inhibitor composition effective to inhibit the angiogenesis or the fibrosis by inhibiting expression and/or activity of a galectin protein or a portion thereof.
    Type: Application
    Filed: May 15, 2015
    Publication date: November 12, 2015
    Inventors: Noorjahan Panjwani, Wei-Sheng Chen, Hakon Leffler, Ulf Nilsson
  • Tissue-engineered silk organs
    Patent number: 9102916
    Abstract: This invention relates to a lamellae tissue layer, comprising a grooved silk fibroin substrate comprising tissue-specific cells. The silk fibroin substrates provides an excellent means of controlling and culturing cell and extracellular matrix development. A multitude of lamellae tissue layers can be used to create a tissue-engineered organ, such as a tissue-engineered cornea. The tissue-engineered organ is non-immunogenic and biocompatible.
    Type: Grant
    Filed: February 27, 2008
    Date of Patent: August 11, 2015
    Assignee: Trustees of Tufts College
    Inventors: David L. Kaplan, Fiorenzo Omenetto, Jeffrey K. Marchant, Noorjahan Panjwani, Brian Lawrence
  • TISSUE-ENGINEERED SILK ORGANS
    Publication number: 20100191328
    Abstract: This invention relates to a lamellae tissue layer, comprising a grooved silk fibroin substrate comprising tissue-specific cells. The silk fibroin substrates provides an excellent means of controlling and culturing cell and extracellular matrix development. A multitude of lamellae tissue layers can be used to create a tissue-engineered organ, such as a tissue-engineered cornea. The tissue-engineered organ is non-immunogenic and biocompatible.
    Type: Application
    Filed: February 27, 2008
    Publication date: July 29, 2010
    Applicant: TRUSTEES OF TUFTS COLLEGE
    Inventors: David L. Kaplan, Fiorenzo Omenetto, Jeffrey K. Marchant, Noorjahan Panjwani, Brian Lawrence
  • Composition and Uses of a Galectin for Treatment of Dry Eye Syndrome
    Publication number: 20100004163
    Abstract: Methods for the therapeutic treatment of dry eye in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-1 protein, a galectin-3, a galectin-7 protein and/or a galectin-8 protein are provided. Pharmaceutical and ophthalmic compositions and kits, comprising a pharmaceutically an active agent which is a galectin-1 protein, a galectin-3 protein, galectin-7 protein and/or a galectin-8 protein, and a suitable carrier or a diluent, are provided.
    Type: Application
    Filed: April 13, 2006
    Publication date: January 7, 2010
    Applicant: Tufts University
    Inventor: Noorjahan Panjwani
  • Use of galectin-7 to promote the re-epithelialization of wounds
    Publication number: 20090270320
    Abstract: Methods for the therapeutic treatment of epithelial wounds in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-3 protein and/or a galectin-7 protein are provided. Pharmaceutical compositions comprising a pharmaceutically suitable carrier or diluent and as an active agent a galectin-3 protein and/or a galectin-7 protein are also provided.
    Type: Application
    Filed: February 27, 2009
    Publication date: October 29, 2009
    Inventors: Noorjahan Panjwani, Zhiyi Cao
  • Compositions and uses of a galectin for treatment of dry eye syndrome
    Patent number: 7189697
    Abstract: Methods for the therapeutic treatment of dry eye in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-1 protein, a galectin-3, a galectin-7 protein and/or a galectin-8 protein are provided. Pharmaceutical and ophthalmic compositions and kits, comprising a pharmaceutically an active agent which is a galectin-1 protein, a galectin-3 protein, galectin-7 protein and/or a galectin-8 protein, and a suitable carrier or a diluent, are provided.
    Type: Grant
    Filed: April 13, 2005
    Date of Patent: March 13, 2007
    Assignee: Trustees of Tufts College
    Inventor: Noorjahan Panjwani
  • Compositions and uses of a galectin for treatment of dry eye syndrome
    Publication number: 20060189514
    Abstract: Methods for the therapeutic treatment of dry eye in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-1 protein, a galectin-3, a galectin-7 protein and/or a galectin-8 protein are provided. Pharmaceutical and ophthalmic compositions and kits, comprising a pharmaceutically an active agent which is a galectin-1 protein, a galectin-3 protein, galectin-7 protein and/or a galectin-8 protein, and a suitable carrier or a diluent, are provided.
    Type: Application
    Filed: April 13, 2005
    Publication date: August 24, 2006
    Inventor: Noorjahan Panjwani
  • Use of galectin-3 and galectin-7 to promote the re-epithelialization of wounds
    Publication number: 20060035817
    Abstract: Methods for the therapeutic treatment of epithelial wounds in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-3 protein and/or a galectin-7 protein are provided. Pharmaceutical compositions comprising a pharmaceutically suitable carrier or diluent and as an active agent a galectin-3 protein and/or a galectin-7 protein are also provided.
    Type: Application
    Filed: August 25, 2005
    Publication date: February 16, 2006
    Inventors: Noorjahan Panjwani, Zhiyi Cao
  • Use of Galectin-3 to promote the re-epithelialization of wounds
    Patent number: 6967021
    Abstract: Methods for the therapeutic treatment of epithelial wounds in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-3 protein and/or a galectin-7 protein are provided. Pharmaceutical compositions comprising a pharmaceutically suitable carrier or diluent and as an active agent a galectin-3 protein and/or a galectin-7 protein are also provided.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: November 22, 2005
    Assignee: Trustees of Tufts College
    Inventors: Noorjahan Panjwani, Zhiyi Cao
  • Use of galectin-3 and galectin-7 to promote the re-epithelialization of wounds
    Publication number: 20040071684
    Abstract: Methods for the therapeutic treatment of epithelial wounds in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-3 protein and/or a galectin-7 protein are provided. Pharmaceutical compositions comprising a pharmaceutically suitable carrier or diluent and as an active agent a galectin-3 protein and/or a galectin-7 protein are also provided.
    Type: Application
    Filed: April 26, 2002
    Publication date: April 15, 2004
    Inventors: Noorjahan Panjwani, Zhiyi Cao
  • Microbe-inhibiting compositions
    Patent number: 6037333
    Abstract: Microbe-inhibiting compositions including N-acetylglucosamine and methods of using them.
    Type: Grant
    Filed: May 7, 1998
    Date of Patent: March 14, 2000
    Assignee: Trustees of Tufts College
    Inventor: Noorjahan A. Panjwani